Overview

Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)

Status:
Recruiting
Trial end date:
2023-05-30
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the effect of dapagliflozin on liver function of patient with NAFLD and T2DM.
Phase:
Phase 4
Details
Lead Sponsor:
Rehab Werida
Collaborator:
University of Alexandria
Treatments:
Dapagliflozin